Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.
Bristol Myers Squibb (BMY) shares rose 1.18% to $57.27 on Friday, marking its third consecutive day of gains despite a broader market decline where the S&P 500 and Dow Jones fell. However, BMY underperformed compared to key competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories, which all posted higher percentage increases. The stock remains 8.93% below its 52-week high.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: MarketWatch Automated The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments